Efficacy and safety of low-dose propiverine in patients with lower urinary tract symptoms/benign prostatic hyperplasia with storage symptoms: A prospective, randomized, single-blinded and multicenter clinical trial

Jae Hyun Bae, Sun Ouck Kim, Eun Sang Yoo, Kyung Hyun Moon, Yoon Soo Kyung, Hyung Jee Kim

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Purpose: The aim of this study was to evaluate whether low-dose anticholinergics combined with an α1-receptor antagonist would continue the effect of an alpha-blocker, decrease the side effects of anticholinergics, and improve the symptoms of lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPH). Materials and Methods: Two hundred nine men with LUTS/BPH with storage symptoms (International Prostate Symptom Score [IPSS] ≥12; storage symptoms ≥4) were randomly assigned in a prospective, multicentered, and single-blind fashion to either the control group (alfuzosin 10 mg, once daily) or the combined group (alfuzosin 10 mg, once daily, and propiverine 10 mg, once daily) for 2 months. IPSS, maximal urinary flow rate (Qmax), and postvoid residual volume (PVR) were used to grade symptoms, side effects, and the impact on quality of life (QoL) at the start of the study and after 1 and 2 months. Results: There were no significant differences in patient background, including age, prostate size, Qmax, and PVR, between the control group and the combined group. In the combined group, the IPSS total score and the IPSS storage symptom score were significantly improved compared with the control group. The IPSS voiding symptom score, QoL, Qmax, and PVR did not differ significantly. There were no serious side effects in either group. Conclusions: Management with an α1-receptor antagonist combined with a low-dose anticholinergic improved the total score and storage symptom score of the IPSS compared with α1-receptor antagonist only group without causing serious side effects. This initial combination medication can be considered an effective and safe treatment modality for LUTS/BPH patients with storage symptoms.

Original languageEnglish
Pages (from-to)274-278
Number of pages5
JournalKorean Journal of Urology
Volume52
Issue number4
DOIs
Publication statusPublished - 2011 Apr 1

Fingerprint

Lower Urinary Tract Symptoms
Prostatic Hyperplasia
Multicenter Studies
Prostate
Clinical Trials
Safety
Residual Volume
Cholinergic Antagonists
Control Groups
Quality of Life
propiverine

Keywords

  • Cholinergic antagonists
  • Propiverine
  • Prostatic hyperplasia

ASJC Scopus subject areas

  • Urology

Cite this

Efficacy and safety of low-dose propiverine in patients with lower urinary tract symptoms/benign prostatic hyperplasia with storage symptoms : A prospective, randomized, single-blinded and multicenter clinical trial. / Bae, Jae Hyun; Kim, Sun Ouck; Yoo, Eun Sang; Moon, Kyung Hyun; Kyung, Yoon Soo; Kim, Hyung Jee.

In: Korean Journal of Urology, Vol. 52, No. 4, 01.04.2011, p. 274-278.

Research output: Contribution to journalArticle

@article{49833e42acd442e9ad2f4677bda9cd00,
title = "Efficacy and safety of low-dose propiverine in patients with lower urinary tract symptoms/benign prostatic hyperplasia with storage symptoms: A prospective, randomized, single-blinded and multicenter clinical trial",
abstract = "Purpose: The aim of this study was to evaluate whether low-dose anticholinergics combined with an α1-receptor antagonist would continue the effect of an alpha-blocker, decrease the side effects of anticholinergics, and improve the symptoms of lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPH). Materials and Methods: Two hundred nine men with LUTS/BPH with storage symptoms (International Prostate Symptom Score [IPSS] ≥12; storage symptoms ≥4) were randomly assigned in a prospective, multicentered, and single-blind fashion to either the control group (alfuzosin 10 mg, once daily) or the combined group (alfuzosin 10 mg, once daily, and propiverine 10 mg, once daily) for 2 months. IPSS, maximal urinary flow rate (Qmax), and postvoid residual volume (PVR) were used to grade symptoms, side effects, and the impact on quality of life (QoL) at the start of the study and after 1 and 2 months. Results: There were no significant differences in patient background, including age, prostate size, Qmax, and PVR, between the control group and the combined group. In the combined group, the IPSS total score and the IPSS storage symptom score were significantly improved compared with the control group. The IPSS voiding symptom score, QoL, Qmax, and PVR did not differ significantly. There were no serious side effects in either group. Conclusions: Management with an α1-receptor antagonist combined with a low-dose anticholinergic improved the total score and storage symptom score of the IPSS compared with α1-receptor antagonist only group without causing serious side effects. This initial combination medication can be considered an effective and safe treatment modality for LUTS/BPH patients with storage symptoms.",
keywords = "Cholinergic antagonists, Propiverine, Prostatic hyperplasia",
author = "Bae, {Jae Hyun} and Kim, {Sun Ouck} and Yoo, {Eun Sang} and Moon, {Kyung Hyun} and Kyung, {Yoon Soo} and Kim, {Hyung Jee}",
year = "2011",
month = "4",
day = "1",
doi = "10.4111/kju.2011.52.4.274",
language = "English",
volume = "52",
pages = "274--278",
journal = "Korean Journal of Urology",
issn = "2005-6737",
publisher = "Korean Urological Association",
number = "4",

}

TY - JOUR

T1 - Efficacy and safety of low-dose propiverine in patients with lower urinary tract symptoms/benign prostatic hyperplasia with storage symptoms

T2 - A prospective, randomized, single-blinded and multicenter clinical trial

AU - Bae, Jae Hyun

AU - Kim, Sun Ouck

AU - Yoo, Eun Sang

AU - Moon, Kyung Hyun

AU - Kyung, Yoon Soo

AU - Kim, Hyung Jee

PY - 2011/4/1

Y1 - 2011/4/1

N2 - Purpose: The aim of this study was to evaluate whether low-dose anticholinergics combined with an α1-receptor antagonist would continue the effect of an alpha-blocker, decrease the side effects of anticholinergics, and improve the symptoms of lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPH). Materials and Methods: Two hundred nine men with LUTS/BPH with storage symptoms (International Prostate Symptom Score [IPSS] ≥12; storage symptoms ≥4) were randomly assigned in a prospective, multicentered, and single-blind fashion to either the control group (alfuzosin 10 mg, once daily) or the combined group (alfuzosin 10 mg, once daily, and propiverine 10 mg, once daily) for 2 months. IPSS, maximal urinary flow rate (Qmax), and postvoid residual volume (PVR) were used to grade symptoms, side effects, and the impact on quality of life (QoL) at the start of the study and after 1 and 2 months. Results: There were no significant differences in patient background, including age, prostate size, Qmax, and PVR, between the control group and the combined group. In the combined group, the IPSS total score and the IPSS storage symptom score were significantly improved compared with the control group. The IPSS voiding symptom score, QoL, Qmax, and PVR did not differ significantly. There were no serious side effects in either group. Conclusions: Management with an α1-receptor antagonist combined with a low-dose anticholinergic improved the total score and storage symptom score of the IPSS compared with α1-receptor antagonist only group without causing serious side effects. This initial combination medication can be considered an effective and safe treatment modality for LUTS/BPH patients with storage symptoms.

AB - Purpose: The aim of this study was to evaluate whether low-dose anticholinergics combined with an α1-receptor antagonist would continue the effect of an alpha-blocker, decrease the side effects of anticholinergics, and improve the symptoms of lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPH). Materials and Methods: Two hundred nine men with LUTS/BPH with storage symptoms (International Prostate Symptom Score [IPSS] ≥12; storage symptoms ≥4) were randomly assigned in a prospective, multicentered, and single-blind fashion to either the control group (alfuzosin 10 mg, once daily) or the combined group (alfuzosin 10 mg, once daily, and propiverine 10 mg, once daily) for 2 months. IPSS, maximal urinary flow rate (Qmax), and postvoid residual volume (PVR) were used to grade symptoms, side effects, and the impact on quality of life (QoL) at the start of the study and after 1 and 2 months. Results: There were no significant differences in patient background, including age, prostate size, Qmax, and PVR, between the control group and the combined group. In the combined group, the IPSS total score and the IPSS storage symptom score were significantly improved compared with the control group. The IPSS voiding symptom score, QoL, Qmax, and PVR did not differ significantly. There were no serious side effects in either group. Conclusions: Management with an α1-receptor antagonist combined with a low-dose anticholinergic improved the total score and storage symptom score of the IPSS compared with α1-receptor antagonist only group without causing serious side effects. This initial combination medication can be considered an effective and safe treatment modality for LUTS/BPH patients with storage symptoms.

KW - Cholinergic antagonists

KW - Propiverine

KW - Prostatic hyperplasia

UR - http://www.scopus.com/inward/record.url?scp=79955695500&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955695500&partnerID=8YFLogxK

U2 - 10.4111/kju.2011.52.4.274

DO - 10.4111/kju.2011.52.4.274

M3 - Article

C2 - 21556215

AN - SCOPUS:79955695500

VL - 52

SP - 274

EP - 278

JO - Korean Journal of Urology

JF - Korean Journal of Urology

SN - 2005-6737

IS - 4

ER -